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Abstract The importance of insulin-like growth factor-1
(IGF-1) in coronary artery disease (CAD) due to wide
range of its biological effects and its therapeutic potential,
has already been described. Our aim was to evaluate pos-
sible inﬂuence of IGF-1 serum level changes on coronary
atherosclerosis. In case of existence of such association our
further aim was to verify and explain this phenomenon by
examination of promoter P1 of IGF-1gene and receptor
gene for IGF-1. The study was performed in 101 consec-
utive patients undergo for routine coronary angiography.
Quantitative and qualitative assessment of coronary ath-
erosclerosis was performed respectively by estimation of
the number of culprit lesions in coronary arteries and by
Gensini score calculation. IGF-1, IGFBP3 and plasma
lipoproteins were measured in all patients. In addition, we
evaluated DNA from 101 patients, isolated from blood
cells, which was ampliﬁed by using PCR with sophisticated
primers for P1 promoter of IGF-1 gene and IGF-1 receptor
gene, then analyzed utilizing SSCP technique and auto-
matically sequenced. We observed signiﬁcant increase of
serum IGF-1 levels in patients with ‘‘3 vessel disease’’ and
with high score in Gensini scale when compared to those
without any narrowing lesions in coronary arteries and 0
Gensini score (in group with 3 vessel disease 215.0 ± 71.3
versuss 176.7 ± 34.2 ng/ml p = 0.04 and with high
Gensini score 231.4 ± 59.3 versus 181.0 ± 37.8 ng/ml
p = 0.01).We found different genotypes for ﬁve P1 pro-
moter polymorphisms of IGF-1 gene (RS35767, RS57426
12, RS228837, RS11829693, RS17879774). There were no
signiﬁcant associations between the observed single
nucleotide polymorphism (SNP) and coronary atheroscle-
rosis nor with levels of circulating IGF-1. We found no
structural polymorphism in receptor gene for IGF-1 nor in
its extracellular domain(exon 2–4) nor in internal domain
(exon 16–21). The effect of increased IGF-1 serum level in
our study was probably independent from structural poly-
morphism in promoter P1 for IGF-1 or in receptor gene for
IGF-1.
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1 Introduction
IGF-1 is a product of IGF-1 gene, which is mapped on 12
chromosome [6]. There are two transcription start sites
located on exon 1 and 2, what results in two different
carboxyl-terminal domains of IGF (Ea and Eb). Eb tran-
scripts are mainly expressed in the liver. Besides this, IGF-
1 is also synthetised in kidneys, kardiomyocytes, VSMC’s,
ﬁbroblasts etc., as a result of (growth hormone) GH-GH
receptor interaction [6].
The importance of insulin-like growth factor-1 (IGF-1)
in coronary artery disease (CAD) due to a wide range of its
biological effects and its therapeutic potential has already
been discussed in literature [1, 6, 8].
A potential proinﬂammatory effect of IGF-1 was
explored by Che (2002) who suggested that IGF-1
enhanced TNF-a -dependent adhesion molecule expression
in cultured bovine VSMC’s [5]. Grant et al. (1996) [9] was
the ﬁrst publication to report lack of IGF-1 expression in
normal coronary arteries and its overexpresion in post-
atherectomy specimens. Okura et al. (2001) and Patel et al.
(2001) [13, 14] described reduction of local IGF-1, IGFR in
advanced plaque, possibly due to proinﬂammatory cyto-
kines, and ox-LDL effect. Reduced IGF-1 expression and
low IGF-1 bioavailability triggered by high level of IG-
FBP4 could be responsible for ox-LDL- induced cytotoxity
and apoptosis in VSMCs. This process could in turn
facilitate plaque instability or rupture [15]. Jansen (1998)
[10] associated high serum IGF-1 levels with decreased
prevalence of CAD.
IGF-1 synthesis is controlled and regulated by various
mechanisms and enzymes. Any of those mechanisms may
contribute to changes in phenotype protein levels [2]. The
efﬁcacy of that process may depend on structure of: IGF-1
gene, gene regulatory sequences or receptor gene for IGF-
1. Our aim was to evaluate possible inﬂuence of IGF-1
serum level changes on coronary atherosclerosis. In case of
existence of such association our further aim was to verify
and explain this phenomenon by examination of promoter
P1 of IGF-1gene and receptor gene for IGF-1. According
to the fact of constitutive properties of IGF-1 gene we did
not decide to analyze its sequence.
2 Materials and Methods
Blood samples were collected from 101 consecutive
patients undergoing routine coronary angiography, at 8.00
AM before catherization, to avoid the effect of daily-
dependence of IGF-1 release rhythm.
2.1 Determination of IGFPB3, IGF-1, Lipoprotein
Levels
IGF-1 serum levels were measured by radio immune assay
technique with the use of commercial kits from Biosource
(Nivelles, Belgium).
The lipid levels were measured using enzymatic kits and
the Architect system (Abbott, San Diego, California).
2.2 Detection of Polymorphisms by SSCP
and by Sequencing
The isolation of genomic DNA with salt-extraction
approach was used as described in [3] and [4]. Subse-
quently, the purity of obtained DNA was assessed with
electrophoresis on 0.8% agarose gel.
Using polymerase chain reaction (PCR) analyses of
sequences of the P1 promoter (divided into 4 fragments:
region a between -1404 to –1134nt, region b between
-1115 to -784nt, region c between -633 to -305nt, and
region d between -250 to ?49nt) of IGF-1 gene as well as
for IGF-1 receptor gene (exons 2–4 and 16–21) were per-
formed for each patient. PCR primers were selected from
IGF-1 gene promoter sequences and IGF-1 receptor gene
sequences taken from the Entrez Gene database. The prod-
uctsofDNAampliﬁcationwereveriﬁedwithelectrophoresis
on 2% agarose gel and analyzed using single strand confor-
mation polymorphism (SSCP) to evaluate IGF-1 gene P1
promoter polymorphism or IGF-1 receptor gene polimor-
phism. DNA fragments were separated by electrophoresis
and underwent further silver staining. Beckman-Coulter
Genetic Analysis System CEQ 2000XL with capillary
electrophoresis technology and ﬂuorescence detection
option was used for automated sequencing, allowing for a
moreaccuratedeterminationofnucleotidesequencechanges
essentialfortheidentiﬁcationoftheIGF-1genepromoterP1
or IGF-1 receptor gene structure.
TRANSFAC system was additionally employed to ﬁnd
transcriptional factors which may hypothetically become
attached to the observed P1 promoter sequence.
2.3 Coronary Images Analysis
The coronarography images were analyzed by quantitative
coronaryangiography(QCA)techniqueandtheGensiniscore
was calculated for quantiﬁcation of arteriosclerotic changes.
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123Gensini score is calculated by assigning to every (even
an insigniﬁcant one) atherosclerotic lesion a suitable
quantity of points, depending on the vessel priority. In such
cases, a 30% narrowing lesion is given more points in
proximal left descending artery than in proximal left cir-
cumﬂex artery.
2.4 Patient Selection
Inclusion criteria for patients was included ‘‘positive’’
result of ECG exercise test, what was established no longer
then 4 weeks before catherization. Patients were excluded
if they displayed acute coronary syndrome, myocardial
infarction (MI) during the preceding 3 months, acute
congestive heart failure (NYHA III/IV), acute or chronic
hematopoietic disease, cancer, acromegaly, or inﬂamma-
tion originating from bacterial, viral, or fungal infections.
The study protocol was approved by the local ethics
committee [4].
2.5 Statistics
Normality was tested in Shapiro–Wilk’s W test. At normal
variables of distribution we used T-Student test (for two
independent variables) or Levene test and analysis of
variances (for multiple independent samples). Mann–
Whitney test (for two independent variables) and Kruskal-
Wallece (for multiple independent samples) test were used
at abnormal variables of distribution. We also used cros-
stabulation tables with one and two tailed Fisher exact, and
v2 Person’s tests. Additionally, we employed Spearman’s
rang correlations and the correlation coefﬁcient (at normal
variable distribution). Statistical analysis was conducted
using STATISTICA 7.0 software. The results are given as
mean ± SD.
The protocol of the study was accepted by a local
committee on human research. Every patient was individ-
ually informed and received study consent form to sign.
3 Results
Characteristics of studied group. 101 consecutive patients
(44 women and 57 men) undergoing coronarography were
involved. The average age was 59.2 ± 10.2 years for men
and 61.1 ± 10.03 years for women. Signiﬁcant lesions
(above 50% of the vessel lumen) in one coronary artery
were observed in 22 subjects (17 Men and 5 Women), in
two arteries in 15 patients (11 M, 4 W), whereas the three
vessel disease was diagnosed in 22 patients (12 M,10 W).
No signiﬁcant changes (less than 30%) in coronary
arteries were found in 32 patients and a group of 10
patients had arteriosclerotic changes between 30 and 50%
of artery lumen. 38 patients (24 M, 14 W) had history of
myocardial infarction (MI), 36 patients (20 M,16 W) had
family history of CAD, history of stroke was positive in 5
patients. Basic clinical parameters are shown in Table 1,
2, 3.
Results of biochemical analysis. Average IGF-1 levels
were 197.5 ± 57.1 ng/ml, and IGFBP3 levels were
2102.7 ± 649.74 ng/ml, whereas mean lipid values for the
groups studied were: total cholesterol (TC) 194.6 ±
51.0 mg/ml, HDL 48.7 ± 15.3 mg/ml, low density lipo-
protein (LDL) 118.1 ± 44.4 mg/ml, triglycerides (TG)
144.2 ± 71.5 mg/ml. We observed signiﬁcant increase of
serum IGF-1 levels in patients with ‘‘3 vessel disease’’ and
with high score in Gensini scale when compared to those
without any narrowing lesions in coronary arteries and 0
Gensini score (in group with 3 vessel disease 215.0 ± 71.3
versuss176.7 ± 34.2 ng/mlp = 0.04andwithhighGensini
Table 1 Characteristics of the
studied group
apoA1 Apoprotein A1, apoB
apoprotein B-100, BMI body
mass index, HDL,LDL
lipoproteins, IGF insulin like
growth factor, Lp(a) lipoprotein
a, TC total cholesterol, TG
triglycerides
* p\0.05
Mean value
± SD in female group
(N 44)
Mean value
± SD in male group
(N 57)
Mean value
± SD in studied group
(N 101)
Weight (kg) 72.7 ± 14.0 82.8 ± 13.83 78.47 ± 14.7
Height (cm) 159.2 ± 6.92 171.57 ± 6.67 166.3 ± 9.12
BMI 28.57 ± 4.52 28.07 ± 4.05 28.28 ± 4.24
Hypertension % 78.6 62 69
Diabetes mellitus% 28.6 21 24.5
Smokers%* 11.9 30 22.4
TC mg/ml 198.7 ± 55.14 191.46 ± 47.88 194.6 ± 50.97
HDL mg/ml 53.31 ± 16.32 45.21 ± 13.58 48.68 ± 15.28
LDL mg/ml 116.59 ± 48.3 119.21 ± 41.65 118.1 ± 44.37
TG mg/ml 144.26 ± 59,12 144.21 ± 79.99 144.2 ± 71.46
IGF-1/BMI kg/m^2 6.571 ± 1.912 7.57 ± 2.57 7.147 ± 2.35
IGF-1 ng/ml 183.71 ± 47.25 207.91 ± 61.88 197.5 ± 57.1
IGFBP3 ng/ml 2210.9 ± 675,9 2021.6 ± 623.13 2102.7 ± 649.74
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123score 231.4 ± 59.3 versus 181.0 ± 37.8 ng/ml p = 0.01).
SigniﬁcantbutweakcorrelationswerefoundbetweenIGF-1
and total cholesterol (R = 0.238, p = 0.02), LDL choles-
terol(R = 0.204,p = 0.04)andTG(R = 0.250,p = 0.01),
but not with other lipoproteins. We observed no signiﬁcant
relation between IGF-1, IGFBP’s, and history of MI (p =/
0.24,0.77/respectively),CADfamilialhistory(p =/0.1,0.12/
respectively), hypertension(p =/0.74,0.95/respectively), or
diabetes type 2 (p =/0.58, 0.15/respectively).
3.1 Results of Genotyping
We observed different single DNA strand migration of P1
promoter of IGF-1 gene/divided into 4 fragments/in 123
samples (in a group of 101 patients in total). In 45 patients
we found 5 polymorphism, previously described in the
NCBI data. We found RS35767 polymorphism at –1245nt,
(29 subjects of genotype C/T and 1 of T/T), which con-
stituted 28.7 and 0.99% of all examined patients (C/T was
Table 2 Characteristics of
groups due to arteriosclerosis
apoA1 Apoprotein A1, apoB
apoprotein B-100, BMI body
mass index, HDL,LDL
lipoproteins, IGF insulin like
growth factor, Lp(a) lipoprotein
a, TC total cholesterol, TG
triglycerides
*p\0.05
Coronary arteries without
narrowing lesions in
coronarography, negative history
of MI, negative familial CAD history,
0 points in Gensini scale mean
value ± SD (N 11)
Signiﬁcant lesions
in all coronary arteries/
three vessels disease/,
mean value ± SD (N 20)
Age [years]* 56.3 ± 9.0 64.5 ± 9.1
Weight [kg] 78.8 ± 16.5 80.8 ± 16.4
Height [cm] 163,8 ± 7,9 167.3 ± 11.3
BMI 29.2 ± 5.2 28.7 ± 3.9
Hypertension % 66.6 80
Diabetes mellitus %* 9.1 30
Smokers%* 8.33 20
TC [mg/ml] 182.0 ± 36.6 199.0 ± 63.2
HDL [mg/m]l 49.6 ± 8.3 47.8 ± 16.8
LDL [mg/m]l 108.0 ± 32.2 120.2 ± 54.4
TG [mg/m]l 125.2 ± 44.4 153.5 ± 61.8
IGF-1/BMI kg/m^2 6.3 ± 1.5 7.6 ± 2.8
IGF-1 [ng/ml]* 176.7 ± 34.2 215.0 ± 71.3
IGFBP3 [ng/ml] 2052.0 ± 488.3 2115.8 ± 738.4
Table 3 Characteristics of
groups due to arteriosclerosis
apoA1 apoprotein A1, apoB
apoprotein B-100, BMI body
mass index, HDL,LDL
lipoproteins, IGF insulin like
growth factor, Lp(a) lipoprotein
a, TC total cholesterol, TG
triglycerides
* p\0.05
Coronary arteries without
narrowing lesions in coronarography,
0 points in gensini scale,
mean value ± SD
(N 18)
Advanced arteriosclerosis
reﬂected by high gensini
score, mean value ± SD (N 9)
Age [years] 56.8 ± 10.0 64.2 ± 10.6
Weight [kg] 77.2 ± 17.4 83.8 ± 10.8
Height [cm] 164.2 ± 8.4 170.2 ± 9.0
BMI 28.4 ± 5.2 29.0 ± 3.3
Hypertension % 64.7 77.8
Diabetes mellitus%* 12.5 33.3
Smokers%* 23.5 11.1
TC [mg/ml] 192.9 ± 38.6 184.4 ± 73.0
HDL [mg/m]l * 50.3 ± 10.5 41.4 ± 7.7
LDL [mg/m]l 116.5 ± 30.8 111.1 ± 59.7
TG [mg/m]l 132.3 ± 48.4 159.4 ± 59.6
IGF-1/BMI kg/m^2 6.5 ± 1.7 8,0 ± 2.3
IGF-1 [ng/ml]* 181.0 ± 37.8 231.4 ± 59.3
IGFBP3 [ng/ml] 2377.2 ± 674.0 2062.1 ± 475.9
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123found in 14/31.82%/of all examined women, in one subject
homozygote of T/T was observed). In 15 men heterozy-
gotes of C/T were in evidence (26.32% of all examined
men). The rest were probably homozygotes of C/C. We
found 2 cases of homozygote A/A for polymorphism
RS11829693 at -933nt, i.e. in 1.98% of the entire exam-
ined population. RS5742612 polymorphism, genotype C/T
(at -540nt of P1 promoter) was observed in seven patients.
The rest were homozygotes T/T. In addition we found two
cases of weak type of polymorphism RS2288377 (hetero-
zygote of genotype A/T at -438nt of P1 promoter), i.e. in
1.98% of all subjects. The rest were probably homozygotes
of T/T. All subjects were homogenus with regard to
genotype A/A of polymorphism RS17879774 in -97nt of
promoter region P1 for IGF-1 gene. A coexistence of
various genotypes are show in Table 4.
We observed signiﬁcant differences in serum high
densinity lipoprotein (HDL) in patients with the presence
of genotype C/T and T/T, compared to those with C/C
genotype for polymorphism RS35767 (43.7 ± 16 vs.
50.6 ± 11.3 mg/dl p = 0.042),.
We did not observe any signiﬁcant association between
observed SNP’s with the degree of coronary atherosclerosis
deﬁned as the number of culprit lesions or the Gensini scale
score.
We found no structural polymorphism in gene for IGF-1
receptor in its extracellular domain (exon 2–4) and internal
domain (exon 16–21).
4 Discussion
There is increasing evidence for the role of IGF-1 in vas-
cular pathologies, including arteriosclerosis, but the func-
tion of this protein is still unclear [12].
We noticed signiﬁcantly elevated circulating levels of
IGF-1 in patients with signiﬁcant obstructive lesions in all
three coronary arteries in contrast to those without changes.
(This information was obtained from the analysis of coro-
nary angiographic images, and later conﬁrmed by the anal-
ysis of Gensini scale score). Even though that IGF-1 levels
are age dependent [7], our experimental group with high
Gensini scores were older and with ‘‘3 vessel disease’’ were
signiﬁcantly older than control patients without narrowing
lesions in coronary arteries. There were no other signiﬁcant
differences between studied groups with regard to parame-
ters which may inﬂuence IGF-1 biosynthesis except for
higher occurrence of diabetes mellitus (DM) in group with
advanced coronary arteriosclerosis. (Tables 2,3). Due to the
fact that DM was related to decreased levels of IGF-1 [6], it
does not interfere with results of our analysis.
The major goal of our study was to ﬁnd a possible
molecular cause of serum IGF-1 level differences in pre-
viously described group of patients. We found 5 polymor-
phisms in P1 promoter region of IGF-1 gene, previously
described in the NCBI database. We additionally used
TRANSFAC system to evaluate possible modulations in
transcriptional factors attached to the observed P1 promoter
sequence. Having analysed data with TRANSFAC system,
we may assume that the disturbed attachment of such fac-
tors as (C/EBP(CCAAT enhancer binding protein) Hoxa-
3,Sp1 (serine protease inhibitor) or GATA-1, (GATA
nucleotide sequence) may have an impact on IGF-1 protein
synthesis, but we did not observed any signiﬁcant correla-
tion between promoter P1 polymorphism and serum IGF-1
levels. To be precise, higher levels of IGF-1 with genotype
A/A of polymorphism RS11829693, and lower levels with
genotype T/T for polymorphism RS35767 were observed,
but the low number of subjects precluded valid statistical
analysis. Besides, these genotypes occur very seldom in a
population, which may lead to a conjecture that their
meaning is marginal.
Genotype C/T for RS5742612 occurred with signiﬁ-
cantly higher frequency in the group of patients with stroke
history (Yates v2 p = 0.046, Test v2 p = 0.03, Fisher
exact, one-tailed p = 0.041, Fisher two-tailed p = 0.041).
Table 4 Frequency of various genotypes
Polymorphism
RS 35767 (genotype
and number of patients)
Polymorphism
RS 11829693
(genotype and
number of patients)
Polymorphism
RS 5742612
(genotype and
number of patients)
Polymorphism
RS 2288377
(genotype and
number of patients)
Various polymorphisms
Female Genotype C/T-14
genotype T/T-1
Genotype A/A-2 Genotype C/T-4 Genotype A/T-1 Two subjects of (A,B)*,
one subject of C*
Male Genotype C/T-15 0 Genotype C/T-3 Genotype A/T-1 One subject of (B)
%F 31.8 5.56 9.09 1.75 5.17
%M 26.3 5.26 2.28 2.28
A* (genotype C/T of RS 35767, genotype A/A of RS 11829693, genotype C/T of RS 5742612), B* (genotype C/T of RS 35767, genotype C/T of
RS 5742612, genotype A/T of RS 2288377, C* (genotype T/T of RS 35767, genotype C/T of RS 5742612)
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123Additionally, the region between –1115 to –784nt (of P1
promoter of IGF-1 gene) underwent a precise analysis, due
to a different number of dinucloetide GC repeats (alleles
Bp192/194-38/42nt in our study). We found higher IGF-1
levels in ‘‘variant carriers’’ (in opposition to Yazdanapah
[16]) [3], without any effect on the progression of coronary
atherosclerosis, what was conﬁrmed by precise GC esti-
mation [4].
‘‘Variant carrier’’ is an artiﬁcial term introduced by
Yazdanapah which describes not a simple genotype but a
few genotypes of GC repeats in region between -1115 to
-784nt of P1 promoter [16]. Therefore it is difﬁcult to
establish their real frequency in population and in our
opinion it is even hard to speculate about its meaning.
The frequency of other alleles for various genotypes
found in our study are comparable to those described in
NCBI database, however, our study had the advantage
collecting data from a large group of subjects. In relevant
literature, the IGF-1 gene is described as constitutive,
therefore we did not analyze the sequence of gene. Nev-
ertheless, we decided to analyze the IGF-1 receptor gene,
responsible for the IGF-1 binding. The analysis have not
shown molecular disturbances in the structure of its
external (exon 2–4) and internal (exon 16–21) domains.
This lead to the conclusion that the increased IGF-1 in
advanced angina patients in our study was probably inde-
pendent from disturbances in sequences of IGF-1 gene or
its promoter P1 as well as IGF-1 receptor gene. We may
only presume that the one of the possible explanation of
increased IGF-1 serum levels in examined subjects could
be the condition of advanced coronary arteriosclerosis.
We surmise that higher levels of serum IGF-1 could be
explained by possible cardioprotective properties of IGF-1.
The escalation of clinical symptoms of angina in the
studied group occurred probably several weeks before
coronary angiography. As discussed in our recent data [3],
it was enough to develop circulating IGF-1 adaptation, in
order to protect lesions (those patients have negative MI
history) from rupture. It is possible that the elevation of
IGF-1, stimulated by persistent myocardial ischemia, could
be a systemic part of heart preconditioning. In case of MI
occurrence it will probably serve as a means of protection
against heart failure. The conﬁrmation of this hypothesis
can be found in the clinical followup of MI subjects in
Friberg study [7]. Poor patients’ prognoses in this trial were
shown to be signiﬁcantly associated with heart failure
occurring after infarction, in consequence of decrease in
systemic IGF-1 levels [7].
There are several limitations of our study. First, we had
not performed echocardiography.
Second we excluded patients with diagnosed clinical
symptoms of peripheral arteriosclerosis due to a fact that
any peripheral arteriosclerosis may inﬂuence the action of
IGF-1 [11]. We did not perform the peripheral doppler
duplex imaging, so it was therefore impossible to exclude
all cases of peripheral arteriosclerosis. Thirdly, coronary
angiography used in our study for quantiﬁcation of coro-
nary arteriosclerosis may also have its limitations (e.g. do
not permit for evaluation of the ‘in-wall’ process). The
ﬁnal limitation of our protocol is the fact of GH (strong
IGF-1 stimulator) estimation only in 38 patients. GH levels
would probably verify whether IGF-1 elevation is caused
only by P1 promoter or receptor gene irregularity. With a
positive conﬁguration of the latter, investigation of possible
clinical importance of the molecular mechanism of eleva-
tion in circulating IGF-1 levels and its association with
lipid metabolism in patients with advanced stable angina
should be established.
5 Conclusion
On the basis of the study protocol we conclude that effect
of increased IGF-1 serum level was probably independent
from IGF-1 gene or its regulating and receptor (extra and
intracellular domain) sequence structure.
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